CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 579 enrolled
Drug / intervention
Sodium risedronatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02106442
NCT02106442N/ACompleted
CompareCT.gov

36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Benet 75 mg Tablets

Takeda·observational·Posted Apr 8, 2014·Updated Jul 30, 2019

In Brief

An observational study evaluating Sodium risedronate for Osteoporosis. Completed, enrolled 579 participants across 2 sites.

Detailed Summary

The purpose of this survey is to evaluate the effectiveness (endpoints: frequency of bone fractures, percent change in bone density, etc.) and safety of administration of sodium risedronate tablets 75 mg for 36 months in osteoporosis patients in daily medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 8, 2014
Enrollment StartMay 13, 2013
Primary CompletionApr 30, 2018
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 12.2 years ago

Interventions

Sodium risedronatedrug

Sodium risedronate tablets